These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21476058)

  • 1. Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.
    Ozkan E; Tokmak E; Kucuk NO
    Ann Nucl Med; 2011 Jul; 25(6):425-31. PubMed ID: 21476058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.
    Chadha MK; Lombardo J; Mashtare T; Wilding GE; Litwin A; Raczyk C; Gibbs JF; Kuvshinoff B; Javle MM; Iyer RV
    Anticancer Res; 2009 Oct; 29(10):4127-30. PubMed ID: 19846960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
    Anthony L; Vinik AI
    Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
    Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
    Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
    Khuroo MS; Khuroo MS; Khuroo NS
    J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
    Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
    Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
    Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
    Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.
    Buscombe JR; Caplin ME; Hilson AJ
    J Nucl Med; 2003 Jan; 44(1):1-6. PubMed ID: 12515868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
    Penning C; Vecht J; Masclee AA
    Aliment Pharmacol Ther; 2005 Nov; 22(10):963-9. PubMed ID: 16268971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatoid arthritis associated with the use of Sandostatin® LAR® depot in a patient with pancreatic neuroendocrine tumor. An association or a coincidence? The first case report.
    Saif MW
    JOP; 2011 Jul; 12(4):425-8. PubMed ID: 21737909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
    di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
    Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
    Pasieka JL; McEwan AJ; Rorstad O
    Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
    Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ
    J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
    Chamberlain MC; Glantz MJ; Fadul CE
    Neurology; 2007 Sep; 69(10):969-73. PubMed ID: 17785665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
    Simonenko VB; Dulin PA; Makanin MA
    Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.
    Shen C; Xu Y; Dasari A; Shih YC; Yao JC
    Oncologist; 2016 Mar; 21(3):308-13. PubMed ID: 26911407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.